NDC 0781-3239-46 - Ciprofloxacin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0781-3239
- Requested NDC
- 0781-3239-46
- Package NDCs from labels
- 0781-3239-46, 0781-3239-09
- Manufacturer
- Sandoz Inc
- Effective date
- 2015-03-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Ciprofloxacin - Sandoz Inc | Sandoz Inc | 2015-03-10 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2013-02-13 | Indexing - Billing Unit |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 0781-3239-09 | 2020-05-07 | C162847 | 48780-1 | 9d75b9d0-c913-f424-e053-dadaa90a57ce | CIPROFLOXACIN INJECTION, USP For Intravenous Infusion |
| 0781-3239-09 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-c913-f424-e053-dadaa90a57ce | CIPROFLOXACIN INJECTION, USP For Intravenous Infusion |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-3239-09 | ML - Milliliter | 0781-3239 | 55d22f44-4b49-4232-93e8-0dbc9b32cbc8 | 1 | 2013-02-13 |
| 0781-3239-46 | ML - Milliliter | 0781-3239 | d50a1dd2-1999-475c-bb8b-c2f9da4f7cc0 | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CIPROFLOXACIN | ACTIVE INGREDIENT | 5E8K9I0O4U | CIPROFLOXACIN INJECTION [SANDOZ INC] | 12 | |
| CIPROFLOXACIN | ACTIVE MOIETY | 5E8K9I0O4U | CIPROFLOXACIN INJECTION [SANDOZ INC] | 12 | |
| DEXTROSE MONOHYDRATE | INACTIVE INGREDIENT | LX22YL083G | CIPROFLOXACIN INJECTION [SANDOZ INC] | 12 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | CIPROFLOXACIN INJECTION [SANDOZ INC] | 12 | |
| LACTIC ACID | INACTIVE INGREDIENT | 33X04XA5AT | CIPROFLOXACIN INJECTION [SANDOZ INC] | 12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e | 2020-02-27 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | LX22YL083G |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | LX22YL083G | |
| DEXTROSE | DEXTROSE MONOHYDRATE | Baxter Healthcare Corporation | 0332f34a-7038-47cc-ba59-d55cad6b73ca | 2019-08-05 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose | POTASSIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 45de5402-5e61-4bbd-8bbc-5e3392c9920e | 2019-07-15 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose and Sodium Chloride | POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE | Baxter Healthcare Company | c553fed1-3de5-4826-8eff-633b5923bf0b | 2019-02-21 | Warnings, Adverse reactions | LX22YL083G |
| OMEOSPORT | .ALPHA.-KETOGLUTARIC ACID - ACONITIC ACID, CIS - ADENOSINE TRIPHOSPHATE - ALPHA LIPOIC ACID - ASCORBIC ACID - ASIAN GINSENG - BARIUM CATION - BEET - CEROUS OXALATE NONAHYDRATE - COENZYME A - CYSTEINE - FUMARIC ACID - LACTIC ACID, DL - MAGNESIUM CARBONATE - MALIC ACID - MANGANESE PHOSPHATE, DIBASIC - PORK - PYRIDOXINE HYDROCHLORIDE - RIBOFLAVIN - SODIUM DIETHYL OXALACETATE - SODIUM PYRUVATE - SUCCINIC ACID - SUS SCROFA ADRENAL GLAND - THIAMINE HYDROCHLORIDE - SUS SCROFA EMBRYO - | Guna spa | 119a205d-0074-48ff-ac78-e2300db45227 | 2018-12-21 | Warnings | 33X04XA5AT |
| Glucose Control T015 | SYZYGIUM JAMBOLANUM, GLANDULA SUPRARENALIS SUIS, HYDRASTIS CANADENSIS, HYPOPHYSIS SUIS, PANCREAS SUIS, PHASEOLUS, ACETICUM ACIDUM, LACTICUM ACIDUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, URANIUM NITRICUM | Guangzhou Renuma Medical Systems Co., Ltd | 3fd02c0a-5cf1-4f35-86d0-d5d09e63f39b | 2017-10-26 | Warnings | 33X04XA5AT |
| e25cd8ac-b616-40a3-b8e5-9e0c72c6393d | 231b60f5-4b72-4f8f-a19e-b7068a601c3a | 2015-03-10 | Boxed warning, Warnings, Adverse reactions | 231b60f5-4b72-4f8f-a19e-b7068a601c3a | ||
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 051f7347-5a76-4664-8fe2-e61b3dfcb0e4 | 2014-08-27 | LX22YL083G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.